MELD 3.0 Score
Updated MELD score incorporating sex (MELD 3.0) for more equitable liver transplant allocation. Approved by UNOS in 2022.
Score interpretation
MELD 3.0 <10. Low short-term mortality (<5%).
→ Manage complications of cirrhosis. Optimise nutrition. Monitor every 3–6 months.
MELD 3.0 10–19. Significant 90-day mortality risk.
→ Consider transplant listing. Manage portal hypertension. Hepatology review.
MELD 3.0 20–29. High short-term mortality.
→ Urgent transplant evaluation. Treat complications (hepatorenal syndrome, SBP). ICU if decompensated.
MELD 3.0 ≥30. Very high mortality without transplant.
→ Active transplant listing. Bridge therapy if available. Palliative care consideration if not transplant-eligible.
Interpretation bands for the MELD 3.0. Apply clinical judgement and local guidance.
References
- Kim WR et al. MELD 3.0: The Model for End-Stage Liver Disease Updated for the 21st Century. Hepatology. 2021;74(4):1732-1743.
Related
Curated clinical cross-links plus same-class fallbacks.
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Sulfasalazine · Aminosalicylate / Disease-Modifying Antirheumatic Drug (DMARD)
- Spironolactone (Ascites / Cirrhosis) · Aldosterone Antagonist / Potassium-Sparing Diuretic
- Furosemide (Ascites / Cirrhosis) · Loop Diuretic
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.